Skip to content
Peptigraph home

Semaglutide for Kidney Disease: What the Evidence Shows

What human and animal studies show about Semaglutide for kidney disease, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
2
with an outcome for kidney disease, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for kidney disease, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
2
with an outcome for kidney disease

Evidence for kidney disease

Each row is an outcome related to kidney disease from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for kidney disease: outcomes in published studies
OutcomeResultStudy typeSource
AlbuminuriaAfter 24 weeks, urinary albumin-to-creatinine ratio was reduced by 52.1% with semaglutide vs placebo.Human RCTn = 101Nature medicine 2025, PMID 39455729
Major kidney disease eventsThe risk of the primary kidney composite was 24% lower with semaglutide (331 vs 410 first events; hazard ratio 0.76).Human RCTn = 3533The New England journal of medicine 2024, PMID 38785209
Major cardiovascular eventsThe risk of major cardiovascular events was 18% lower (hazard ratio 0.82).Human RCTn = 3533The New England journal of medicine 2024, PMID 38785209

Semaglutide and kidney disease are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Nature medicine 2025, PMID 39455729

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Chronic kidney disease and the FLOW trial

MedlinePlus says the kidneys remove wastes and extra water, which become urine.[3]

FLOW enrolled 3533 people with type 2 diabetes and chronic kidney disease, and it was stopped early after an interim analysis.[2]

The risk of a primary kidney-and-cardiovascular event was 24% lower with semaglutide than with placebo, with a hazard ratio of 0.76.[2]

The kidney filtration rate declined less steeply on semaglutide, by about 1.16 ml per minute per 1.73 m2 each year.[2]

Kidney disease without diabetes

A smaller placebo-controlled trial in people with overweight or obesity and non-diabetic kidney disease measured urine albumin, a kidney damage marker, over 24 weeks; it was not a long outcomes trial like FLOW.[1]

In that trial gastrointestinal side effects were reported by 30 people on semaglutide and 15 on placebo.[1]

Label and safety points for kidney patients

The Ozempic label includes an indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.[4]

The label also carries a warning about acute kidney injury from volume depletion, with postmarketing reports in some cases requiring hemodialysis.[4]

Other peptides people research for kidney disease

No other peptide in our index has a kidney disease page yet.

Common questions

Does Semaglutide help with kidney disease?

The strongest study we summarise for kidney disease is human rct evidence, across 2 studies with an outcome for kidney disease. A trial result is not an approval; see the legal status.

Is Semaglutide approved for kidney disease?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

Is semaglutide good for kidney disease?

In people with type 2 diabetes and chronic kidney disease, the FLOW trial found fewer primary kidney and cardiovascular events with semaglutide; evidence outside diabetes is limited to a smaller albuminuria trial.[2]

Does semaglutide harm the kidneys?

The label warns of acute kidney injury when volume depletion occurs, and advises monitoring kidney function in affected patients.[4]

Is semaglutide safe if I already have CKD?

The Ozempic label says no dose adjustment is recommended for kidney impairment, based on pharmacokinetic data; this is a label statement, not personal advice.[4]

More on Semaglutide

Sources

  1. 1Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
  2. 2Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
  3. 3medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  4. 4OZEMPIC prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.